What is the current valuation of the Malaria Vaccine Market?

The Malaria Vaccine Market was valued at 0.8498 USD Billion in 2024. Read More

What is the projected market size for the Malaria Vaccine Market by 2035?

The market is projected to reach 8.404 USD Billion by 2035. Read More

What is the expected CAGR for the Malaria Vaccine Market during the forecast period 2025 - 2035?

The expected CAGR for the Malaria Vaccine Market during 2025 - 2035 is 23.16%. Read More

Which companies are the key players in the Malaria Vaccine Market?

Key players include GlaxoSmithKline, Pfizer, Sanofi, Merck & Co., Novartis, Johnson & Johnson, Bharat Biotech, Takeda Pharmaceutical Company, and Medicago. Read More

What are the main types of malaria vaccines currently available?

The main types include RTS, S/AS01, R21/Matrix-M, and PfSPZ, with valuations of 0.4249, 0.2549, and 0.1699 USD Billion respectively. Read More

What are the primary administration routes for malaria vaccines?

The primary administration routes are intramuscular and subcutaneous, each valued at 0.4249 USD Billion. Read More

Who are the target populations for malaria vaccination?

Target populations include children under 5 years, pregnant women, and travelers to endemic areas, with valuations of 0.425, 0.2, and 0.224 USD Billion respectively. Read More

What immunization schedules are being utilized for malaria vaccines?

Immunization schedules include single dose, multi-dose, and booster doses, with valuations of 0.2549, 0.3398, and 0.2551 USD Billion respectively. Read More

What stages of development are malaria vaccines currently in?

Malaria vaccines are in various stages, including preclinical, clinical trials, and marketed, with valuations of 0.2549, 0.3399, and 0.2549 USD Billion respectively. Read More

How does the Malaria Vaccine Market's growth compare to other vaccine markets?

The Malaria Vaccine Market's growth appears robust, with a projected valuation increase from 0.8498 USD Billion in 2024 to 8.404 USD Billion by 2035. Read More

Malaria Vaccine Market

Malaria Vaccine Market Research Report: Size, Share, Trend Analysis By Vaccine Type (RTS, S/AS01, R21/Matrix-M, PfSPZ), By Administration Route (Intramuscular, Subcutaneous), By Target Population (Children under 5 years, Pregnant women, Travelers to endemic areas), By Immunization Schedule (Single dose, Multi-dose, Booster doses), By Development Stage (Preclinical, Clinical Trials, Marketed) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

23.16%

2024 Market Size

$ 0.85 Billion

2035 Market Size

$ 8.4 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/39111-HCR | Pages: 100 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type (USD Billion) | |
  1. 4.1.1 RTS, S/AS01 | |
  2. 4.1.2 R21/Matrix-M | |
  3. 4.1.3 PfSPZ |
2. 4.2 Healthcare, BY Administration Route (USD Billion) | |
  1. 4.2.1 Intramuscular | |
  2. 4.2.2 Subcutaneous |
3. 4.3 Healthcare, BY Target Population (USD Billion) | |
  1. 4.3.1 Children under 5 years | |
  2. 4.3.2 Pregnant women | |
  3. 4.3.3 Travelers to endemic areas |
4. 4.4 Healthcare, BY Immunization Schedule (USD Billion) | |
  1. 4.4.1 Single dose | |
  2. 4.4.2 Multi-dose | |
  3. 4.4.3 Booster doses |
5. 4.5 Healthcare, BY Development Stage (USD Billion) | |
  1. 4.5.1 Preclinical | |
  2. 4.5.2 Clinical Trials | |
  3. 4.5.3 Marketed |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 GlaxoSmithKline (GB) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Pfizer (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Sanofi (FR) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Merck & Co. (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Novartis (CH) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Johnson & Johnson (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Bharat Biotech (IN) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Takeda Pharmaceutical Company (JP) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Medicago (CA) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE |
7. 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE |
8. 6.5 US MARKET ANALYSIS BY TARGET POPULATION |
9. 6.6 US MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
10. 6.7 US MARKET ANALYSIS BY DEVELOPMENT STAGE |
11. 6.8 CANADA MARKET ANALYSIS BY TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
13. 6.10 CANADA MARKET ANALYSIS BY TARGET POPULATION |
14. 6.11 CANADA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
15. 6.12 CANADA MARKET ANALYSIS BY DEVELOPMENT STAGE |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
19. 6.16 GERMANY MARKET ANALYSIS BY TARGET POPULATION |
20. 6.17 GERMANY MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
21. 6.18 GERMANY MARKET ANALYSIS BY DEVELOPMENT STAGE |
22. 6.19 UK MARKET ANALYSIS BY TYPE |
23. 6.20 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE |
24. 6.21 UK MARKET ANALYSIS BY TARGET POPULATION |
25. 6.22 UK MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
26. 6.23 UK MARKET ANALYSIS BY DEVELOPMENT STAGE |
27. 6.24 FRANCE MARKET ANALYSIS BY TYPE |
28. 6.25 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
29. 6.26 FRANCE MARKET ANALYSIS BY TARGET POPULATION |
30. 6.27 FRANCE MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
31. 6.28 FRANCE MARKET ANALYSIS BY DEVELOPMENT STAGE |
32. 6.29 RUSSIA MARKET ANALYSIS BY TYPE |
33. 6.30 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
34. 6.31 RUSSIA MARKET ANALYSIS BY TARGET POPULATION |
35. 6.32 RUSSIA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
36. 6.33 RUSSIA MARKET ANALYSIS BY DEVELOPMENT STAGE |
37. 6.34 ITALY MARKET ANALYSIS BY TYPE |
38. 6.35 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
39. 6.36 ITALY MARKET ANALYSIS BY TARGET POPULATION |
40. 6.37 ITALY MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
41. 6.38 ITALY MARKET ANALYSIS BY DEVELOPMENT STAGE |
42. 6.39 SPAIN MARKET ANALYSIS BY TYPE |
43. 6.40 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
44. 6.41 SPAIN MARKET ANALYSIS BY TARGET POPULATION |
45. 6.42 SPAIN MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
46. 6.43 SPAIN MARKET ANALYSIS BY DEVELOPMENT STAGE |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY TARGET POPULATION |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY DEVELOPMENT STAGE |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY TYPE |
54. 6.51 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
55. 6.52 CHINA MARKET ANALYSIS BY TARGET POPULATION |
56. 6.53 CHINA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
57. 6.54 CHINA MARKET ANALYSIS BY DEVELOPMENT STAGE |
58. 6.55 INDIA MARKET ANALYSIS BY TYPE |
59. 6.56 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
60. 6.57 INDIA MARKET ANALYSIS BY TARGET POPULATION |
61. 6.58 INDIA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
62. 6.59 INDIA MARKET ANALYSIS BY DEVELOPMENT STAGE |
63. 6.60 JAPAN MARKET ANALYSIS BY TYPE |
64. 6.61 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
65. 6.62 JAPAN MARKET ANALYSIS BY TARGET POPULATION |
66. 6.63 JAPAN MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
67. 6.64 JAPAN MARKET ANALYSIS BY DEVELOPMENT STAGE |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY TARGET POPULATION |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY DEVELOPMENT STAGE |
73. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE |
74. 6.71 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
75. 6.72 MALAYSIA MARKET ANALYSIS BY TARGET POPULATION |
76. 6.73 MALAYSIA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
77. 6.74 MALAYSIA MARKET ANALYSIS BY DEVELOPMENT STAGE |
78. 6.75 THAILAND MARKET ANALYSIS BY TYPE |
79. 6.76 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE |
80. 6.77 THAILAND MARKET ANALYSIS BY TARGET POPULATION |
81. 6.78 THAILAND MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
82. 6.79 THAILAND MARKET ANALYSIS BY DEVELOPMENT STAGE |
83. 6.80 INDONESIA MARKET ANALYSIS BY TYPE |
84. 6.81 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
85. 6.82 INDONESIA MARKET ANALYSIS BY TARGET POPULATION |
86. 6.83 INDONESIA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
87. 6.84 INDONESIA MARKET ANALYSIS BY DEVELOPMENT STAGE |
88. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE |
89. 6.86 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE |
90. 6.87 REST OF APAC MARKET ANALYSIS BY TARGET POPULATION |
91. 6.88 REST OF APAC MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
92. 6.89 REST OF APAC MARKET ANALYSIS BY DEVELOPMENT STAGE |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY TYPE |
95. 6.92 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE |
96. 6.93 BRAZIL MARKET ANALYSIS BY TARGET POPULATION |
97. 6.94 BRAZIL MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
98. 6.95 BRAZIL MARKET ANALYSIS BY DEVELOPMENT STAGE |
99. 6.96 MEXICO MARKET ANALYSIS BY TYPE |
100. 6.97 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE |
101. 6.98 MEXICO MARKET ANALYSIS BY TARGET POPULATION |
102. 6.99 MEXICO MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
103. 6.100 MEXICO MARKET ANALYSIS BY DEVELOPMENT STAGE |
104. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE |
105. 6.102 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
106. 6.103 ARGENTINA MARKET ANALYSIS BY TARGET POPULATION |
107. 6.104 ARGENTINA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
108. 6.105 ARGENTINA MARKET ANALYSIS BY DEVELOPMENT STAGE |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET POPULATION |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY DEVELOPMENT STAGE |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TARGET POPULATION |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY DEVELOPMENT STAGE |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TARGET POPULATION |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY DEVELOPMENT STAGE |
125. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE |
126. 6.123 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
127. 6.124 REST OF MEA MARKET ANALYSIS BY TARGET POPULATION |
128. 6.125 REST OF MEA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
129. 6.126 REST OF MEA MARKET ANALYSIS BY DEVELOPMENT STAGE |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY TARGET POPULATION, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY TARGET POPULATION, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY IMMUNIZATION SCHEDULE, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY IMMUNIZATION SCHEDULE, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY DEVELOPMENT STAGE, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY DEVELOPMENT STAGE, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY TARGET POPULATION, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY DEVELOPMENT STAGE, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Malaria Vaccine Market Segmentation

Malaria Vaccine Market By Type (USD Billion, 2025-2035)

RTS, S/AS01
R21/Matrix-M
PfSPZ

Malaria Vaccine Market By Administration Route (USD Billion, 2025-2035)

Intramuscular
Subcutaneous

Malaria Vaccine Market By Target Population (USD Billion, 2025-2035)

Children under 5 years
Pregnant women
Travelers to endemic areas

Malaria Vaccine Market By Immunization Schedule (USD Billion, 2025-2035)

Single dose
Multi-dose
Booster doses

Malaria Vaccine Market By Development Stage (USD Billion, 2025-2035)

Preclinical
Clinical Trials
Marketed

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”